LeMaitre Vascular, Inc. (NASDAQ:LMAT) Increases Dividend to $0.25 Per Share

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Thursday, February 19th. Investors of record on Thursday, March 12th will be paid a dividend of 0.25 per share by the medical instruments supplier on Thursday, March 26th. This represents a c) annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. This is a 25.0% increase from LeMaitre Vascular’s previous quarterly dividend of $0.20.

LeMaitre Vascular has raised its dividend by an average of 0.2%per year over the last three years and has increased its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a payout ratio of 42.0% meaning its dividend is sufficiently covered by earnings. Analysts expect LeMaitre Vascular to earn $2.17 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 46.1%.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $110.07 on Tuesday. The firm has a fifty day simple moving average of $89.84 and a 200 day simple moving average of $88.81. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $115.33. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $2.51 billion, a PE ratio of 43.85, a P/E/G ratio of 3.09 and a beta of 0.66.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. LeMaitre Vascular’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, sell-side analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 55,930 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the transaction, the chief executive officer owned 1,476,500 shares of the company’s stock, valued at $159,181,465. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the transaction, the insider owned 6,677 shares of the company’s stock, valued at $736,406.33. The trade was a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 215,438 shares of company stock valued at $23,062,911 over the last ninety days. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust grew its position in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 287 shares during the period. Cornerstone Planning Group LLC lifted its position in shares of LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 283 shares in the last quarter. MAI Capital Management bought a new stake in LeMaitre Vascular during the 3rd quarter valued at approximately $38,000. First Horizon Corp bought a new position in LeMaitre Vascular in the 3rd quarter worth approximately $39,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.